In Memoriam: Joel Smilow

We are deeply saddened to share the news that Joel Smilow passed away at Yale New Haven Hospital on Sunday, October 3, 2021, after a brief illness. Mr. Smilow and his wife, Joan, generously gave the transformational gift to build Smilow Cancer Hospital at Yale New Haven in 2008. He was dedicated to transforming the lives of cancer patients through his philanthropic support and was a wonderful friend and supporter to all of us at Smilow Cancer Hospital.

Mr. Smilow’s business career started at Procter & Gamble as an Assistant Brand Manager in 1958. He joined Playtex Products in 1970 and became chair, CEO, and president of Playtex International before his retirement in 1995. Following his retirement, Mr. Smilow focused his time on numerous diverse charitable activities, including at healthcare facilities across the country, and locally at Yale supporting his beloved Yale Bulldogs with the Joel E. Smilow Field Center and several endowed coaching positions. Mr. Smilow was awarded the Yale Medal in 1993 and named a Sterling Fellow in recognition of his outstanding contributions to Yale University.

Mr. Smilow’s generosity has made a significant impact on cancer care for our patients. Smilow Cancer Hospital is the only facility in the Northeast that fully integrates both inpatient and outpatient cancer care into one building. The foundational support from Mr. and Mrs. Smilow has transformed cancer care at Yale New Haven Health over the last decade and will continue to influence us as we plan for our next decade of cancer care throughout the Smilow Cancer Hospital Network.

We offer our profound sympathy to Mrs. Smilow and the entire Smilow family during this difficult time. Mr. Smilow has left a legacy here and we are truly grateful for his support of Smilow Cancer Hospital, and for sharing in our vision of creating a place of hope for cancer patients.
Pamela Kunz, MD, Named Woman Oncologist of the Year

Women Leaders in Oncology (WLO) has named Pamela Kunz, MD, the 2021 Woman Oncologist of the Year. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief of GI Medical Oncology and Vice Chief, Diversity Equity and Inclusion, Medical Oncology. The award honors a senior professional who is a respected individual in her field and who has modeled excellence in leadership. It also recognizes a woman who exhibits strong business acumen and the ability to share her skills with others. Kunz was presented the award virtually October 1, 2021, during the annual Leadership Empowerment and Development (LEAD) conference.

Dr. Kunz was selected from a field of 51 women nominated by WLO conference attendees. Beyond her record of accomplishment in gastrointestinal oncology, Kunz is an international leader in the clinical care of patients with neuroendocrine tumors and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis. In addition, she is also a leading voice for promoting gender equity in the medical workforce.

Learn More

Notables

The National Cancer Institute (NCI) has recognized Markus Müschen, MD, PhD, Director of the Center of Molecular and Cellular Oncology, Arthur H. and Isabel Bunker Professor of Hematology, and Professor of Immunobiology, with its Outstanding Investigator Award. The award supports scientists with outstanding records of productivity and innovation and provides more than $7 million in funding over seven years for groundbreaking cancer research.

Elizabeth Berger, MD, Assistant Professor of Surgery (Surgical Oncology) has been named a prestigious Michael Zinner Health Services Research Fellow by the Surgical Outcomes Club.

The National Cancer Institute has announced a U19 cooperative grant to establish a Glioblastoma Therapeutics Network (GTN) to work collaboratively to develop new treatments for adult glioblastoma. Antonio Omuro, MD, Professor of Neurology and Chief of Neuro-Oncology, and Ranjit Bindra, MD, PhD, Professor of Therapeutic Radiology, are Principal Investigators for the U19 and the associated grant, "Center of Innovation for Brain Tumor Therapeutics." Learn More

Congratulations to Daniel Petrylak, MD, Professor of Medicine (Medical Oncology), for his work in breast cancer research and treatment.
Congratulations to Daniel Petrylak, MD, Professor of Medicine (Medical Oncology) and Urology, appointed Vice Chairman of the SWOG Cancer Research Network Genitourinary Committee.

Xavier Llor, MD, PhD, Professor of Medicine (Digestive Diseases) and Director of the Smilow Genetics and Prevention Program, and Erin Hofstatter, MD, Adjunct Professor of Medicine (Medical Oncology), have published a book, “Cancer Genetics: A Clinical Approach,” with the expertise of many Yale Cancer Center members. The text is available online.

Sabrina Browning, MD, Assistant Professor of Medicine (Hematology), has been appointed to serve as the faculty representative for the faculty divisions of Yale Cancer Center to the Dean's Advisory Council from November 2021 to October 2024.

The Yale Surgery Citizen Awards Committee has named Ronald Salem, MD, FACS, MBChB, Lampman Professor of Surgery (Surgical Oncology) the 2022 recipient of The Dr. Walter E. Longo MD Award. Established in 2019, the award recognizes one faculty member per year who has made a significant positive influence on the cultural legacy of the Department of Surgery.

Nita Ahuja, MD, MBA, Interim Director of Yale Cancer Center, Interim Physician-in-Chief of Smilow Cancer Hospital, and Chief of Surgery, has been appointed Chair-Elect of the Council of Faculty and Academic Societies (CFAS) for the Association of American Medical Colleges (AAMC). CFAS serves to identify and voice critical issues facing medical school faculty, within the structure of governance at AAMC — the major nonprofit association that represents all 149 accredited U.S. medical schools, nearly 400 major teaching hospitals and academic medical systems, and more than 80 academic and scientific societies.

The following Yale Cancer Center members presented CAPE (Cancer Action Prevention Engagement at Yale) Team Poster Presentations at the 14th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved on October 6-8, 2021.

Impact of health navigation program on healthy lifestyle and cancer screening in population with significant social determinants of health (SDOH) barriers. Monique Stefanou, Sakinah C. Suttiratana, Denise Stevens, Eduardo Reyes, Jonathan Colon, Roy Herbst, Beth A. Jones.

Qualitative Analysis of Case Notes and Narratives Reported by Community Health Navigators in the Yale Cancer Disparities Firewall Project. Sakinah C. Suttiratana, Monique Stefanou, Eiman Ibrahim, Jonathan Colon, Eduardo Reyes, Roy Herbst, Beth A. Jones.


Implementing evidence-based interventions (EBI) to increase uptake of fecal immunochemical test (FIT) colorectal cancer (CRC) screening in Vulnerable Populations. Beth A. Jones, Sakinah C Suttiratana, Sally A DeGiovanni, Levita Y Robinson, Michael J Couturie, Denise Stevens, Sally A DeGiovanni, Michele A. Davis, Michael J. Couturie, Denise Stevens.
Introduction of Implicit Bias Training to oncology faculty as a quality improvement initiative. Renee Taylor, Andrea LM Silber.

Successful Lynch syndrome testing strategy among ethnic/racial groups Vinit Singh, Amanda Ganzak, Peter Gershkovich, Joanna Gibson, Rosa M. Xicola, Xavier Llor.

Yale Cancer Center is pleased to announce our call for nominations for our annual awards in the areas of excellence in research, teaching, mentorship, and clinical care. Each award winner will be announced at the Yale Cancer Center Conclave in January (date TBD). The nomination deadline for all awards (unless otherwise noted) is November 1, 2021.

Yale Cancer Center Research Prizes: Research Prizes will be awarded in support of excellence in the areas of basic science, clinical science, translational science, and population science. Awards will be chosen in each area to recognize a paper that is considered to have had the greatest impact on the field this year. The nominee must be a current member of Yale Cancer Center, and the science in the publication must be cancer-focused. To be eligible, the nominee must also be either the first or last author of the publication. Please submit a PDF of the publication (publication date must be between October 2020 to October 2021) along with the category it should be considered for via email to Anna Raso.

Yale Cancer Center Award for Clinical Excellence: This award will be given to the physician who best exemplifies excellence in clinical care including outstanding clinical skills, use of a patient- and family-centered approach to care, and inclusion of a multi-disciplinary care model. Nominee must be a current member of Yale Cancer Center. Please nominate outstanding candidates and send a brief nomination letter (one-page maximum) via email to Anna Raso.

Yale Cancer Center Award for Mentorship Excellence: This award will be given to the faculty member who best exemplifies excellence in mentorship by providing ongoing feedback and support, serving as a role model to their mentee(s), inspiring them in their passion for cancer care or for their specific field of study, providing opportunities and resources for mentee(s) to advance their careers, and encouraging their mentee(s) to grow, strive for excellence, and achieve their full potential. Nominee must be a current member of Yale Cancer Center. Please nominate outstanding candidates and send a brief nomination letter (one-page maximum) via email to Anna Raso.

Yale Cancer Center Award for Teaching Excellence: This award will be given to the faculty member who best exemplifies excellence in teaching by ensuring their trainee(s) acquire the skills they need to develop as outstanding health practitioners, scientists, and/or researchers, providing ongoing feedback, inspiring passion for cancer care or for their specific field of study, explaining difficult concepts in innovative and creative ways, and stimulating excitement, debate, and critical and independent thinking. Nominee must be a current member of Yale Cancer Center. Please nominate outstanding candidates and send a brief nomination letter (one-page maximum) via email to Anna Raso.
Yale Cancer Center Award for Teaching Excellence: This award will be given to the faculty member who best exemplifies excellence in teaching by ensuring their trainee(s) acquire the skills they need to develop as outstanding health practitioners, scientists, and/or researchers, providing ongoing feedback, inspiring passion for cancer care or for their specific field of study, explaining difficult concepts in innovative and creative ways, and stimulating excitement, debate, and critical and independent thinking. Nominee must be a current member of Yale Cancer Center. Please nominate outstanding candidates and send a brief nomination letter (one-page maximum) via email to Anna Raso.

Yale Cancer Center Lifetime Achievement Award: Yale Cancer Center recognizes the achievements of one of our senior members through our annual Lifetime Achievement award. Nominee must be a current member of Yale Cancer Center. Please send nomination suggestions for the award via email to Anna Raso.

Ruth McCorkle Oncology Advanced Practice Provider Award: This annual award from Yale Cancer Center/Smilow Cancer Hospital recognizes the contributions of our Nurse Practitioner and Physician Assistant colleagues who contribute so much to oncology patient care. Please consider nominating yourself or a colleague for this award. Nominations are due for the Ruth McCorkle Award to J.C. Carley by November 30, 2021. Link to Nomination Form

Diversity, Equity, and Inclusion

Hispanic Heritage Month
As we conclude Hispanic Heritage Month (now sometimes called Latinx Heritage Month) today, we celebrate the contributions of the many Yale Latinx faculty, trainees, and staff to our work, our achievements, and our interconnectedness. We also take this occasion to renew our commitment to our Latinx patients to provide a welcoming environment for cancer care, and a research agenda which addresses the disproportionate cancer burden in the Latinx community. The Yale Latino Networking Group (YLNG) is open to all and strives to build a support network for Latino staff at all levels, and to strengthen our professional and social relationships between Latino employees, the university, and the outside community.

Barbara Burtness, MD, in HemOnc Today
Dr. Barbara Burtness, Interim Associate Cancer Center Director for Diversity, Equity, and Inclusion, shared her perspectives on her new role, and building foundations of culture at Yale Cancer Center and Smilow Cancer Hospital. “The first thing we want to be sure of is that we are building the foundations of a culture that can treat everyone equally,” Dr. Burtness said. “A big part of the role is going to be recruitment and retention efforts. There are a lot of strategies we are working on for that, but the most important thing is to ensure that the culture newly recruited people find at our cancer center is fair, welcoming and respectful. It will be difficult to make real progress over time without making sure our culture is truly inclusive.”

How Are We Personalizing Breast Cancer Care?
Employee Profile: J.C. Carley

J.C. Carley is a Senior Administrative Assistant to Kim Slusser, VP Patient Services, Maureen Major Campos, Director, Ambulatory Nursing, Tracy Carafeno, Director, Inpatient Nursing, and Michele Kelvey-Albert, Director of Quality and Patient Safety in Smilow Administration. J.C. joined the Smilow team in January of 2020 after running a wedding photography business for 20 years.

"I have the privilege of supporting four passionate, dedicated oncology nursing leaders. Through organization, forward-thinking and a can-do attitude, I strive to be an island of calm in their busy and sometimes stressful days, so they can keep their headspace clear to make the big decisions that count," said J.C.

In addition to her daily responsibilities, this year J.C. enjoyed facilitating the Smilow Patient and Family Advisory Council, assisting with ambulatory recruitment events, and coordinating a research study with Kim Slusser aimed at retirement aged nurses and exploring ways to help retain them, and their experience, in the workforce longer.

"It is an honor to be leaned upon not just for administrative help, but for strategic counsel, technical expertise, and critical analysis," said J.C. She is also incredibly proud to work amongst an amazing team of administrative assistants at YNHHS. "Every day I learn something new from our masters of 'calendar Tetris,' 'MacGyver's of problem solving,' and 'Julie McCoy's of event planning.' They are truly an amazing and dedicated team."

Ms. Slusser commented, "We are so fortunate to have J.C. on our Smilow team. She is such a thoughtful and caring individual, and it shows in her daily interactions with our teams. Since J.C. joined our team, she has increasingly taken on more project facilitation and works with our PFAC, Luminary Awards planning committee, Smilow Nursing Rewards and Recognition committee, and coordinates many of our patient services meetings. I know I can always depend on J.C., but most importantly, I just really enjoy working with her and appreciate her dedication and commitment."

Recent Publications

Blondin, N.
As a medical oncologist specializing in gastrointestinal cancers, Dr. John Marshall was outspoken in his resentment and envy of the dominance of breast cancer advocacy and research. But then his wife, Liza, was diagnosed at age 43 with a high-risk breast cancer.

Meet John and Liza Marshall on Tuesday, October 19 at the Westport Library (or virtually!) with Dr. Pamela Kunz, medical oncologist at Yale Cancer Center and Smilow Cancer Hospital. John and Liza will share their story of how a cancer diagnosis made them look at medicine, healing, and marriage with a new lens.


Bakhoum MF, Curtis EJ, Goldbaum MH, Mischel PS.  
**BAP1 Methylation: a Prognostic Marker of Uveal Melanoma Metastasis.**  
*NPJ Precision Oncology,* 5(1):89.

Katz SG, Edappallath S, Xu ML.  
**IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias.**  

Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S.  
**Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate-risk, Early-stage Endometrial Cancer Following Vaginal Brachytherapy.**  
*Gynecologic Oncology,* Online ahead of print.

**Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation.**  
*JCO Oncology Practice,* 17(10):607-614.

Neumann N, Thompson DC, Vasiliou V.  
**AMPK Activators for the Prevention and Treatment of Neurodegenerative Diseases.**  
*Expert Opinion on Drug Metabolism & Toxicology,* Online ahead of print.

**Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.**  

Ly CL, Khetpal S, Heller DR, Higgins SA, Killelea B, Alperovich M, Avraham T.  
**Comparing Complications in Irradiated and Non-irradiated Free-flaps in Patients with Bilateral Immediate Breast Reconstruction and Unilateral Post-astectomy Radiotherapy.**  
*Microsurgery,* 41(7):615-621.

Han G, Pusztai L, Hatzis C.  
**Data Augmentation Based on Waterfall Plots to Increase Value of Response Data Generated by Small Single Arm Phase II Trials.**  
*Contemporary Clinical Trials,* Online ahead of print.

"The knowledge that you gather in your endeavor may be seemingly of no immediate consequence, but it will contribute to the collective understanding & lead to breathtaking advances." —Dr. Victor Chang, medical oncologist at our Smilow Cancer Care Center in Waterbury, shares his perspective on a career in cancer research.
Zeidan AM, Salimi T, Epstein RS. 
Real-world Use and Outcomes of Hypomethylating Agent Therapy in Higher-Risk Myelodysplastic Syndromes: Why Are We Not Achieving the Promise of Clinical Trials? 
*Future Oncology*, Online ahead of print. 
Read More

Performing Calcitonin Immunocytochemistry on an Additional ThinPrep Slide in Fine-Needle Aspiration Diagnosis of Medullary Thyroid Carcinoma. 
*American Journal of Clinical Pathology*, Online ahead of print. 
Read More

Funding and Award Opportunities

**AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga**
This award has been established to honor the life and legacy of Dr. José Baselga, who was a scientific leader and supportive mentor to an entire generation of physician-scientists. Dr. Baselga’s research focused on novel molecular targeted therapeutics and he played a leading role in the clinical development of multiple cancer drugs. 
**Letter of Intent Due:** October 19, 2021 
Read More

**CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity**
CRI invites applications from candidates who identify as Black or African American, Hispanic or Latino/a American, or American Indian or Alaska Native. CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system’s role in cancer. 
**Application Deadline:** October 21, 2021 
Read More

**Women’s Health Research Pilot Project Grants: Studying Women and the Influence of Sex & Gender on Health**
WHRY Pilot Project Program funds studies providing new approaches to understanding the health of women, and/or the influence of sex/gender differences on health. Studies that advance our understanding of sex or gender in addressing the coronavirus pandemic will also be reviewed for funding. 
**Letters of Intent Due:** October 21, 2021 
Read More

**National Cancer Institute Youth Enjoy Science Research Education Program (R25)**
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. 
Read More

As Breast Cancer Awareness Month launches, Smilow Cancer Hospital celebrates progress that has been made. “We have come a long way in the past 50 years with breast cancer treatments, allowing women to remain physically and emotionally whole without compromising on excellent cancer outcomes,” says Rachel Greenup, MD, MPH, chief of Breast Surgical Oncology at Smilow Cancer Hospital.

Throughout the month of October, we will share updates from The Breast Center at Smilow Cancer Hospital, educational programs, and support for our patients and their families.

Follow Yale Cancer Center on Twitter

Congratulations to @DanielPetrylak who will be officially appointed Vice Chairman of the @SWOG genitourinary committee at the #SWOGonc group meeting today.

For #LiverCancerAwarenessMonth, @MarioStrazzabos @YaleLiverCancer shares his thoughts. “Advances are being made on all fronts. Most recent in the treatment of #HCC. The road is still long, but we understand the direction now.”
Youth Enjoy Science (YES) Program (R25)
The NCI YES Program supports educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.  
**Application Deadline:** October 28, 2021  
Read More

Debbie's Dream Foundation Career Development Award for Gastric Cancer Research  
This award supports junior faculty to conduct gastric cancer research and to establish a successful career path in this field.  
**Application Deadline:** October 28, 2021  
Read More

Research Supplements to Promote Re-Entry and Re-integration into Health-Related Research Careers  
The goal of this program is to provide support for a mentored research training experience for individuals with high potential to re-enter or re-integrate into an active research career, after an interruption for family responsibilities or other qualifying circumstances.  
**First Available Due Date:** November 1, 2021  
Read More

Blavatnik Fund for Innovation at Yale  
The Blavatnik Fund for Innovation at Yale, made possible by a generous grant from the Blavatnik Family Foundation, supports Yale faculty in the commercialization of applied research and technology in the life sciences.  
The Fund is expanding its reach beyond therapeutics and medical devices and calling for applicants working in the digital health, healthcare IT and related spaces to submit proposals for funding consideration.  
**Application Deadline:** November 1, 2021  
Read More

Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54)  
The purpose of this FOA is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.  
**Application Deadline:** November 1, 2021  
Read More

Acquired Resistance to Therapy Network (ARTNet; U54)  
The ARTNet FOA is a new funding opportunity that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence.  
**Application Deadline:** November 1, 2021  
Read More
Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24)
The overarching goal of the ARTNet is to bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. The Coordinating Center will assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative, and data management activities of the ARTNet.

Application Deadline: November 1, 2021

Cancer Research Institute Clinical and Laboratory Integration Program (CLIP) Immunotherapy
CLIP supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.

Letter of Intent Due: November 1, 2021

Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01)
The purpose of this FOA is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes.

Application Deadline: November 1, 2021

NCI Research Specialist Awards (Laboratory-based Scientist) Award (R50)
This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

Application Deadline: November 1, 2021

NCI Research Specialist (Core-based Scientist) Award (R50)
This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

Application Deadline: November 1, 2021

Research by Dr. Jong Woo Lee & @BarbaraBurtness presented @AACR NCI-EORTC conf. shows combining a AURKA inhibitor w/a KRAS or a WEE1 inhibitor proved effective for lungcancer resistant to KRAS inhibition.

Calendar

Yale Cancer Answers
October 17; 7:30 PM
NPR
COVID Vaccine and PET Scans: What you need to know
Darko Pucar, MD, PhD
Learn More

Radiobiology and Genome Integrity Research Program
October 18; 11:00 AM
Peptide Nucleic Acids: Antisense Applications for CRISPR-Cas9 Modulation
Nicholas Economos
Learn More

Genetics Clinical Grand Rounds
October 19; 10:15 AM
Human Ring Chromosome Disorders: From Regional Case Collection to Global Collaboration
Peining Li, PhD
Learn More

Schwartz Rounds
October 19; 12:00 PM
Off Our Chests
Dr. John and Liza Marshall
Learn More

Digestive Diseases
October 19; 5:00 PM
AASLD Presentations
Michael Nathanson, MD, PhD
Learn More

Book Signing: Off Our Chests at the Westport Library
October 19; 7:00 PM
Pamela Kunz, MD | Dr. John & Lisa Marshall
Learn More

Yale Head and Neck SPORE’s Monthly Meeting
Melanoma Research Alliance RFPs
The MRA is pleased to announce RFPs for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

Team Science Award LOI Due: October 6, 2021
Young Investigator Award Checklist Due: November 3, 2021
Pilot Awards Due: November 3, 2021

AACR-Conquer Cancer®, the ASCO Foundation Young Investigator Award for Translational Cancer Research
This award provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this jointly-supported award is to fund a physician-scientist during the transition from a fellowship program to a faculty appointment. Research projects are restricted to translational cancer research.

Application Deadline: November 9, 2021

AACR-Bristol Myers Squibb Midcareer Female Investigator Grant
This grant represents a joint effort to encourage and support mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology.

Application Deadline: November 11, 2021

Research Centers for Cancer Systems Biology (U54)
The NCI supports the application of systems biology approaches to cancer research through the CSBC. The CSBC includes U01 Research Projects and, through this FOA, U54 Research Centers. These multi-project Research Centers should address challenges in basic cancer biology that require a coordinated systems biology approach.

Application Deadline: November 12, 2021

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01, R21)
Through this FOA, the NCI invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.

Application Deadline: November 12, 2021

Pancreatic Cancer Detection Consortium: Research Units (U01)
Through this FOA, the NCI is soliciting applications for the Research Units (RU), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursors, aiming to identify the most effective and highly efficient means to detect PDAC.

Application Deadline: November 12, 2021

Meeting
October 20; 7:00 PM
Learn More

Smilow Shares
October 20; 6:00 PM
Learn More

General Internal Medicine Grand Rounds
October 21; 7:30 AM
Breast Imaging in Primary Care
Ilana Richman, MD, MS
Learn More

YSM Black Postdoc Association Presents
October 21; 12:00 PM
Emerging Scholars Seminar Series
Dr. Tikvah K. Hayes
Learn More

Pathology Grand Rounds
October 21; 12:30 PM
The Process and Challenges of the Who Blue Book
Ian Cree, MD, BMSc, MBChB, PhD, FRCPath, ALS
Learn More

Cancer Genetics and Prevention Seminar
October 21; 2:30 PM
Learn More

OBGYN Diversity Grand Rounds
October 21; 4:00 PM
Implicit Bias Training
Darin Latimore, MD
Learn More

Center for GI Cancers Weekly Seminar
October 21; 4:15 PM
Social Media Overview
Mark Lewis
Learn More

Digestive Health Virtual CME Series 2021
October 21; 5:00 PM
H-Pylori
Kenneth Hung, MD, MS
Learn More

Identifying and Caring for Individuals with High Risk & Inherited Cancer Syndromes
Learn More
precursor lesions to identify those patients who are at high risk of progression to cancer.

Application Deadline: November 15, 2021
Read More

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24)
Through this FOA, the NCI is soliciting applications for the establishment of the Management and Data Coordination Unit (MDCU), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC).

Application Deadline: November 15, 2021
Read More

Mobile Health: Technology and Outcomes in Low- and Middle-Income Countries (R21/R33)
The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs.

Application Deadline: November 15, 2021
Read More

Cancer Research Institute Technology Impact Award
These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.

Letter of Intent Due: November 15, 2021
Read More

Alex's Lemonade Stand Foundation (ALSF) Innovation Grants
ALSF seeks game-changing proposals to substantially advance childhood cancer treatments and cures. Innovation Grants provide seed funding to experienced investigators with hypothesis-driven research to develop novel and promising ideas.

Letter of Intent Due: November 15, 2021
Read More

Limited Competition: Coordinating Center for the Small Cell Lung Cancer Consortium (U24)
The purpose of this limited competition FOA is to continue support for the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium that will be focused on prevention, diagnosis, treatment, and mechanisms of treatment resistance in SCLC.

Application Deadline: November 17, 2021
Read More

Understanding Oral HPV Infection, Acquisition, and Persistence in People Living with HIV (R01, R21)
The purpose of these FOAs are to solicit research to better understand the epidemiology and biology of oral HPV infection, its acquisition and persistence among individuals with HIV, and the contribution of oral HPV infection to the development and progression of oropharyngeal squamous cell carcinoma.
persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV.

**Application Deadline:** November 18, 2021

**Read More**

**A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U01)**

Through this FOA, the NCI solicits applications for CUSP2CT, a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials, NCI's Community Oncology Research Program, and Experimental Therapeutics Clinical Trials Network.

**Application Deadline:** November 19, 2021

**Read More**

**Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U24)**

The purpose of this FOA is to solicit applications for Connecting Underrepresented Populations to Clinical Trials U24 Data, Evaluation and Coordinating Center.

**Application Deadline:** November 19, 2021

**Read More**

**ASCI’s 2022 Young Physician-Scientist Awards**

With these awards, the ASCI seeks to recognize early-career physician-scientists who have made notable achievements in their research, and to encourage and inspire them through their participation in the Joint Meeting and related programming.

**Application Deadline:** November 22, 2021

**Read More**

**Launching soon: ASCI Emerging-Generation Awards**

These awards recognize post-MD, pre-career physician-scientists who are meaningfully engaged in immersive research, giving them access to the Joint Meeting and longitudinal programming similar to the YPSA program. Entry into the ASCI network at this stage is intended to provide peer support and inspiration to stay the course into a physician-scientist faculty appointment. Look for E-Gen Awards nominations to open in late October. Contact programs@the-asci.org for more information.

**AACR Clinical Oncology Research (CORE) Training Fellowships**

Designed for early-career clinical scientists who hold a medical degree (MD, DO, or MD/PhD) and are interested in acquiring the knowledge and skills related to clinical trial design and execution from the perspective of the pharmaceutical industry. The fellow will gain real-world experience in drug development, including clinical research, clinical trial design, and data analysis.

**Application Deadline:** November 30, 2021

**Read More**

**AACR Career Development Award to Further Diversity, Equity, and Inclusion in Clinical Cancer Research**

This award has been established to support the development and diversity of
highly talented cancer researchers from underrepresented groups (as per NIH guidelines) in the field of clinical cancer research.

**Application Deadline:** November 30, 2021

**Read More**

**Breast Cancer Research Foundation-AACR Career Development Awards to Promote Diversity and Inclusion**

These awards represent a focused effort to encourage and support investigators from diverse backgrounds traditionally excluded in cancer research and to foster their career advancement. This grants program also intends to build a more diverse and inclusive future for breast cancer research.

**Application Deadline:** November 30, 2021

**Read More**

**Howard Hughes Medical Institute: Hanna H. Gray Fellows Program 2022**

HHMI seeks to increase diversity in the biomedical research community. The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those individuals from disadvantaged backgrounds.

**Application Deadline:** December 1, 2021

**Read More**

**The Hope Foundation for Cancer Research SEED Fund for SWOG Early Exploration and Development 2021**

These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. $50,000

**Application Deadline:** December 1, 2021

**Read More**

**Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)**

The purpose of this FOA is to support and accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

**Application Deadline:** December 15, 2021

**Read More**